Cerebral Therapeutics, Inc.
Mr. Zanon’s responsibilities include oversight of preformulation, formulation development, analytical development, and preclinical toxicology studies including bioanalytical development and analysis. He holds degrees in biochemistry from Northern Michigan University and has over 20 years of broad experience in pharmaceutical development. His key areas of expertise include solubility; salt and form selection; solution, suspension and solid oral dosage formulations; direct compression; extrusion/spheronization; modified-release microparticulate coatings; and preclinical study design. Prior to joining Cerebral Therapeutics in early 2020, his experience in pharmaceutical development was accumulated through positions of increasing responsibility while with G.D. Searle, Pharmacia Corporation, Amgen, and Upsher-Smith.
This person is not in any offices
Cerebral Therapeutics, Inc.
Cerebral Therapeutics is a clinical-stage pharmaceutical company dedicated to improving the lives of patients living with uncontrolled neurological diseases, with an initial focus on refractory epilepsy.